{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:04:47Z","timestamp":1770984287875,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bcp.2018.07.016","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T14:19:35Z","timestamp":1531923575000},"page":"455-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of human sulfotransferases on the cytotoxicity of 12-hydroxynevirapine"],"prefix":"10.1016","volume":"155","author":[{"given":"Jia-Long","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Loukotkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Chitranshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gon\u00e7alo","family":"Gamboa da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick A.","family":"Beland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2018.07.016_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/dkm432","article-title":"Once-daily dosing of nevirapine in HAART","volume":"61","author":"Clotet","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.016_b0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa062876","article-title":"Response to antiretroviral therapy after a single, peripartum dose of nevirapine","volume":"356","author":"Lockman","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.016_b0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1258\/095646206777323346","article-title":"Nevirapine toxicity","volume":"17","author":"Taiwo","year":"2006","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.bcp.2018.07.016_b0020","unstructured":"PDR, Viramune (Nevirapine). Physicians' Desk Reference, Physicians\u2019 Desk Reference, Medical Economics Co., Montvale, NJ, 2009, pp. 873\u2013881."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.016_b0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1468-1293.2006.00396.x","article-title":"Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash","volume":"7","author":"Manosuthi","year":"2006","journal-title":"HIV Med."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.016_b0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/135965350901400203","article-title":"A new era of antiretroviral drug toxicity","volume":"14","author":"Calmy","year":"2009","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.016_b0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jac\/dkt359","article-title":"Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions","volume":"69","author":"Marinho","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.016_b0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/dmd.109.028688","article-title":"Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries","volume":"38","author":"Srivastava","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.016_b0045","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.02294-12","article-title":"ANRS12154 Study Group, Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state","volume":"57","author":"Fan-Havard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.016_b0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/bmc.1353","article-title":"A sensitive and specific liquid chromatography\/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons","volume":"24","author":"Ren","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"16","key":"10.1016\/j.bcp.2018.07.016_b0055","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/rcm.3136","article-title":"A liquid chromatography\/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons","volume":"21","author":"Liu","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.016_b0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.016_b0065","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0090-9556(24)14954-9","article-title":"Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.016_b0070","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.016_b0075","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/tx800177k","article-title":"Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash","volume":"21","author":"Chen","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.016_b0080","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/tx8000972","article-title":"Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine","volume":"21","author":"Antunes","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.016_b0085","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1021\/tx900443z","article-title":"Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine \u2013 a possible factor in nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"issue":"11","key":"10.1016\/j.bcp.2018.07.016_b0090","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/tx100186t","article-title":"Protein adducts as prospective biomarkers of nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.016_b0095","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.3390\/molecules18054955","article-title":"2'-Deoxythymidine adducts from the anti-HIV drug nevirapine","volume":"18","author":"Antunes","year":"2013","journal-title":"Molecules"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2018.07.016_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2012.06.013","article-title":"Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity","volume":"301","author":"Caixas","year":"2012","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.016_b0105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1021\/tx4000107","article-title":"Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients","volume":"26","author":"Meng","year":"2013","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.016_b0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfj061","article-title":"Human sulfotransferases and their role in chemical metabolism","volume":"90","author":"Gamage","year":"2006","journal-title":"Toxicol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.07.016_b0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0009-2797(00)00202-7","article-title":"Sulfotransferases in the bioactivation of xenobiotics","volume":"129","author":"Glatt","year":"2000","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.016_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/toxsci\/kfv311","article-title":"Human sulfotransferases enhance the cytotoxicity of tolvaptan","volume":"150","author":"Fang","year":"2016","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.016_b0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mrgentox.2009.05.006","article-title":"The formation and biological significance of N7-guanine adducts","volume":"678","author":"Boysen","year":"2009","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bcp.2018.07.016_b0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1054-3589(08)61038-8","article-title":"Carcinogen activation by sulfate conjugate formation","volume":"27","author":"Michejda","year":"1994","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.016_b0135","unstructured":"J.-L. Fang, Y. Wu, L. Loukotkov\u00e1, P. Chitranshi, G. Gamboa da Costa, F.A. Beland, Cytotoxicity of 12-sulfoxynevirapine, The Toxicologist SOT 2017 Annual Meeting (Abstract 2234) (2017) 292."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.016_b0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mrgentox.2011.09.003","article-title":"Study of oxidative DNA damage in TK6 human lymphoblastoid cells by use of the thymidine kinase gene-mutation assay and the in vitro modified comet assay: determination of No-Observed-Genotoxic-Effect-Levels","volume":"726","author":"Platel","year":"2011","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bcp.2018.07.016_b0145","series-title":"Principles of Toxicology Testing\/Chapter 17 Mutagenicity and Carcinogenicity Testing in Vitro","first-page":"229","author":"Barile","year":"2013"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.016_b0150","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2131\/jts.38.741","article-title":"Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine","volume":"38","author":"Fang","year":"2013","journal-title":"J. Toxicol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.016_b0155","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1021\/tx800133d","article-title":"Pentachlorophenol and other chlorinated phenols are substrates for human hydroxysteroid sulfotransferase hSULT2A1","volume":"21","author":"Gulcan","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.016_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/138920006774832596","article-title":"Inhibition of sulfotransferases by xenobiotics","volume":"7","author":"Wang","year":"2006","journal-title":"Curr. Drug Metab."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T21:40:41Z","timestamp":1751751641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218302843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":32,"alternative-id":["S0006295218302843"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.016","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of human sulfotransferases on the cytotoxicity of 12-hydroxynevirapine","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}